← back to search

Rudolf Prager

Clinical Trial Investigators ·
Area of research
Endocrinology, Diabetes and Metabolism · Surgery
Research interest
Research interests include Diabetes Treatment and Management, Diabetes Management and Research, Pancreatic function and diabetes, and Diabetes and associated disorders.
h-index
48
citations
10,564
works
193
NIH funding
primary concept
Medicine
email

Recent publications

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis
Diabetes Care 2022cited by 194position: middledoi
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Diabetes & Endocrinology 2021cited by 176position: middledoi
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
The Lancet 2019cited by 603position: middledoi
Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
The Lancet Diabetes & Endocrinology 2019cited by 269position: middledoi
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
Diabetes Care 2018cited by 234position: middledoi
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
The Lancet 2017cited by 837position: middledoi
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
The Lancet Diabetes & Endocrinology 2017cited by 291position: middledoi
A <scp>E</scp> uropean, multicentre, retrospective, non‐interventional study ( <scp>EU‐TREAT</scp> ) of the effectiveness of insulin degludec after switching basal insulin in a population with type 1 or type 2 diabetes
Diabetes Obesity and Metabolism 2017cited by 44position: middledoi
Effects of smoking cessation on β-cell function, insulin sensitivity, body weight, and appetite
European Journal of Endocrinology 2013cited by 82position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 1 papers (2013–2013) · 1 papers (2013–2013)Michael Wolzt · University of California System1 papers (2013–2013)Giovanni Pacini · San Francisco General Hospital1 papers (2013–2013) · 1 papers (2013–2013) · 1 papers (2017–2017)Thorsten Siegmund · Technical University of Munich1 papers (2017–2017) · 1 papers (2017–2017) · 1 papers (2013–2013)Marietta Stadler · King's College London1 papers (2013–2013) · 1 papers (2017–2017)Annunziata Lapolla · University of Padua1 papers (2017–2017)Nikolaοs Tentolouris · Laiko General Hospital of Athens1 papers (2017–2017)Márta Korbonits · Queen Mary University of London1 papers (2013–2013)Søren Tang Knudsen · University of Copenhagen1 papers (2017–2017)Paul Bech · Imperial College Healthcare NHS Trust1 papers (2013–2013) · 1 papers (2013–2013) · 1 papers (2013–2013)